Ernexa Therapeutics (ERNAW) Invested Capital (2010 - 2026)

Ernexa Therapeutics has reported Invested Capital for 17 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 215.97% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (up 215.97% YoY), and the FY2025 full-year result was $2.4 million, up 43.56% from the prior year.
• Invested Capital for Q1 2026 stood at $6.9 million, up from $2.4 million in the prior quarter.
• The five-year high for Invested Capital was $17.3 million in Q1 2022, with the low at -$40.5 million in Q3 2024.
• Historically, Invested Capital has averaged $2.0 million across 5 years, with a median of $3.6 million in 2025.
• Annual changes were most pronounced in 2024 — Invested Capital sank 1236.08% — and 2026, when it soared 215.97%.
• Ernexa Therapeutics' Invested Capital stood at $13.9 million in 2022, then plunged by 83.89% to $2.2 million in 2023, then decreased by 23.82% to $1.7 million in 2024, then surged by 43.56% to $2.4 million in 2025, then soared by 182.56% to $6.9 million in 2026.
• The last three Invested Capital figures came in at $6.9 million (Q1 2026), $2.4 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.